Epsilogen
PrivateLast Round
Series B
Extension
Sep 9, 2024
Total Funding Raised
$74.64M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Epsilogen is a biotechnology company that develops immunoglobulin E (IgE) antibodies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Epsilogen Comparables
Compare Epsilogen with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Pan Cancer T | 72% | |
| Alligator Bioscience | 71% | |
| Abcely | 70% |
Epsilogen Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B Extension | Sep 9, 2024 | ||||
| Series B | Mar 2, 2022 | ||||
| Grant | Oct 22, 2020 | ||||
| Grant | Jul 20, 2020 | ||||
| Series A Extension | Apr 20, 2020 | ||||
Grant | Apr 2, 2019 |
Key People
Founding team and executive leadership
Epsilogen Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Innovate UK | Grant |
| UK government | Grant |
| Epidarex Capital | Series B, Series A, Series A Extension, Series B Extension |
| 3B FUTURE Health Fund | Series B Extension, Series B |
| ALSA Ventures | Series B Extension, Series A, Series A Extension, Series B |
| British Patient Capital | Series B Extension, Series B |
| ALSA Holdings | Series B Extension, Series A, Series A Extension, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 65% MoM, reaching 1.8K.
- Oct 7, 2025
Cristina Oliva appointed as Chief Medical Officer.
Epsilogen Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Epsilogen's valuation, stock price, and market status.
Is Epsilogen a public or private company?
Epsilogen is a private company.
What is the current stock price of Epsilogen?
Epsilogen is a private company with no public stock price. No recent secondary market data is available.
How much is Epsilogen worth (valuation)?
Valuation information for Epsilogen is not publicly available.
Can I buy Epsilogen stock?
Epsilogen shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Epsilogen's last funding round?
Epsilogen's most recent funding round was Series B Extension on September 9, 2024.
Who are the main investors in Epsilogen?
Key investors in Epsilogen include Innovate UK, Epidarex Capital.
Will Epsilogen IPO soon?
No public IPO plans have been announced for Epsilogen.
How can I track Epsilogen secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Epsilogen's secondary market activity and sign up for updates.